Rein Therapeutics Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $14.2M | $10.3M | $7.8M |
| SG&A Expense | $8.8M | $7.9M | $5.1M |
| Operating Income | $-23.0M | $-18.2M | $-12.9M |
| Operating Margin | — | — | — |
| Interest Expense | — | — | — |
| Pretax Income | — | — | — |
| Income Tax Expense | $0 | $0 | — |
| Net Income | $-22.6M | $-18.1M | $-12.9M |
| Net Margin | — | — | — |
| EPS (Basic) | $-0.76 | $-10.59 | $-8.08 |
| EPS (Diluted) | $-0.76 | $-10.59 | $-8.08 |
| Shares Outstanding (Basic) | 58.9M | 1.7M | — |
| Shares Outstanding (Diluted) | 58.9M | 1.7M | — |
| Dividends Per Share | $0.00 | $0.00 | — |